BTIG Maintains 'Neutral' Rating on Geron (GERN) Following Imetelstat Update

September 13, 2016 6:39 AM EDT
Get Alerts GERN Hot Sheet
Price: $2.06 -0.48%

Rating Summary:
    5 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 27 | New: 7
Trade GERN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

BTIG affirms Geron Corp. (Nasdaq: GERN) with a Neutral rating following an update on the ongoing imetelstat Phase II IMbark trial in MF and Phase II/III trial in MDS.

Analyst Ling Wang noted the following key points late Monday:

  • Imetelstat showed consistent safety profile in both trials. Safety profile of imetelstat was consistent with prior observations and no new AEs were observed, which is positive in our view.
  • Update on IMbark. The decision to close the 4.7 mg/kg arm is not surprising, since IMbark is a dose-refining trial. Although it is slightly disappointing that the 9.4 mg/kg arm did not meet the pre-specified criteria (details not disclosed), we understand the IMbark patients (relapsed/refractory MF population, a true unmet need) are more treatment-experienced than in the prior pilot study, which may require longer follow-up and/or additional dose-refining to ascertain the efficacy in this patient population. Additional interim analysis is expected in 2Q17, which Janssen believes should have a sufficient number of patients and follow-up to inform the future development plan of this dose.
  • IMerge trial continues unmodified. Safety and efficacy of imetelstat are consistent with a prior pilot study in MDS patients. Additional assessment will occur in 2Q17 as well. A go-no-go decision will be made based on the benefit/risk analysis of these patients.

For an analyst ratings summary and ratings history on Geron Corporation click here. For more ratings news on Geron Corporation click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities


Add Your Comment